

Global Hypophosphatasia Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-11 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Hypophosphatasia Treatment Market Report and Forecast 2023-2031

Global Hypophosphatasia Treatment Market Outlook

The global hypophosphatasia (HPP) treatment market is projected to grow at a CAGR of 5.10% during the forecast period of 2023-2031. The market growth can be attributed to the increasing prevalence of hypophosphatasia and the rising awareness about the disease and its treatment.

Global Hypophosphatasia Treatment Market: Introduction

Hypophosphatasia treatment refers to the medical care provided to individuals with hypophosphatasia, a rare metabolic bone disorder that affects the development and maintenance of healthy bones and teeth. The treatment options include enzyme replacement therapy, symptomatic management, and supportive care. The increasing prevalence of hypophosphatasia, along with the rising awareness about the disease and its treatment options, are expected to drive market growth.

Technological advancements have also played a significant role in the growth of the HPP treatment market. The development of novel therapies and improved diagnostic tools have made HPP treatment more effective and accessible. In addition, growing investments in research and development to explore new treatment options are expected to fuel market growth.

Global Hypophosphatasia Treatment Market- Epidemiology

Hypophosphatasia is a rare genetic disorder that occurs in various forms, ranging from severe and life-threatening to relatively mild. The disease prevalence varies based on the severity and population studied. It is estimated that the severe forms of HPP affect 1 in 100,000 live births, while milder forms may affect 1 in 6,370 individuals. The increasing prevalence of HPP and improved diagnostic capabilities are driving the demand for effective HPP treatments.

Hypophosphatasia Treatment Market Segmentations

The market can be segmented based on by type, diagnosis methods, treatment methods, treatment channel, and region:

Market Breakup by Type

- Perinatal
- Infantile
- Childhood
- Adult

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Odontohypophosphatasia
- Pseudohypophosphatasia
- Market Breakup by Treatment Type

Market Breakup by Diagnosis Method

- X-rays
- Biochemical Tests
- Chorionic Villus Sampling (CVS)
- Ultrasounds
- Vitamin B6 Test

Market Breakup by Treatment Method

- Medications
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Vitamin B6
- Others
- Dental Care
- Physical Therapy
- Occupational Therapy

Market Breakup by Treatment Channel

- Public
- Private

Market Breakup by Region

- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Others

Hypophosphatasia Treatment Market Analysis

The global HPP treatment market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of hypophosphatasia, rising awareness about the disease, and growing demand for effective treatment options.

North America is currently the largest market for HPP treatment, followed by Europe and the Asia Pacific. The growth in the North American market is primarily driven by factors such as a high prevalence of hypophosphatasia, a well-established healthcare infrastructure, and strong investment in research and development. In addition, the growing adoption of novel therapies and improved diagnostic tools is further driving the growth of the market in North America.

Europe is also a significant market for HPP treatment, with countries such as Germany and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of HPP, and government initiatives to address rare disease concerns. Additionally, the region has a well-established healthcare system, which supports the delivery of HPP treatment. Asia Pacific is another region that is experiencing significant growth in the HPP treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of HPP, and the growing adoption of novel therapies. In addition, government initiatives to address rare disease concerns are helping to drive the growth of the market in the region.

Key Players in the Global Hypophosphatasia Treatment Market

The report provides a detailed analysis of the key players involved in the HPP treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

- Kirin Holdings Company
- Vericel Corporation
- Mereo BioPharma Group plc
- Novartis AG
- Bayer AG
- AM-Pharma B.V.
- Alexion
- Pfizer, Inc.
-

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
- 2 Research Methodology
- 3 Executive Summary
- 4 Hypophosphatasia Overview
 - 4.1 Guidelines and Stages
 - 4.2 Pathophysiology
 - 4.3 Screening and Diagnosis
 - 4.4 Treatment Pathway
- 5 Patient Profile
 - 5.1 Patient Profile Model
 - 5.2 Patient Psychology and Emotional Impact Factors
 - 5.3 Risk Assessment and Treatment Success Rate
- 6 Current Scenario Evaluation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1 Emerging Therapies and Clinical Trials Synopsis
- 6.2 Patent Landscape and Impact
- 6.3 Cost of Treatment
- 6.4 Others
- 7 Challenges and Unmet Needs
 - 7.1 Treatment Pathway Challenges
 - 7.2 Compliance and Drop- out Analysis
 - 7.3 Awareness and Prevention Gaps
- 8 Global Hypophosphatasia Treatment Market
 - 8.1 Global Hypophosphatasia Treatment Market Overview
 - 8.2 Global Hypophosphatasia Treatment Market Analysis
 - 8.2.1 Market Overview
 - 8.2.1.1 Global Historical Hypophosphatasia Treatment Market Value (2016-2022)
 - 8.2.1.2 Global Forecast Hypophosphatasia Treatment Market Value (2023-2031)
 - 8.2.2 Global Hypophosphatasia Treatment Market by Type
 - 8.2.2.1 Market Overview
 - 8.2.2.1.1 Perinatal
 - 8.2.2.1.2 Infantile
 - 8.2.2.1.3 Childhood
 - 8.2.2.1.4 Adult
 - 8.2.2.1.5 Odonto-hypophosphatasia
 - 8.2.2.1.6 Pseudo-hypophosphatasia
 - 8.2.3 Global Hypophosphatasia Treatment Market by Diagnosis Method
 - 8.2.3.1 Market Overview
 - 8.2.3.1.1 X-rays
 - 8.2.3.1.2 Biochemical Tests
 - 8.2.3.1.3 Chorionic Villus Sampling (CVS)
 - 8.2.3.1.4 Ultrasounds
 - 8.2.3.1.5 Vitamin B6 Test
 - 8.2.4 Global Hypophosphatasia Treatment Market by Treatment Method
 - 8.2.4.1 Market Overview
 - 8.2.4.1.1 Medications
 - 8.2.4.1.1.1 Nonsteroidal anti-inflammatory drugs (NSAIDs)
 - 8.2.4.1.1.2 Vitamin B6
 - 8.2.4.1.1.3 Others
 - 8.2.4.1.2 Dental Care
 - 8.2.4.1.3 Physical Therapy
 - 8.2.4.1.4 Occupational Therapy
 - 8.2.5 Global Hypophosphatasia Treatment Market by Treatment Channel
 - 8.2.5.1 Market Overview
 - 8.2.5.1.1 Public
 - 8.2.5.1.2 Private
 - 8.2.6 Global Hypophosphatasia Treatment Market by Region
 - 8.2.6.1 Market Overview
 - 8.2.6.1.1 North America
 - 8.2.6.1.2 Europe
 - 8.2.6.1.3 Asia Pacific

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.6.1.4 Latin America
- 8.2.6.1.5 Middle East and Africa
- 9 North America Hypophosphatasia Treatment Market
 - 9.1 Market Share by Country
 - 9.2 United States of America
 - 9.2.1 Historical Trend (2016-2022)
 - 9.2.2 Forecast Trend (2023-2031)
 - 9.3 Canada
 - 9.3.1 Historical Trend (2016-2022)
 - 9.3.2 Forecast Trend (2023-2031)
- 10 Europe Hypophosphatasia Treatment Market
 - 10.1 Market Share by Country
 - 10.2 United Kingdom
 - 10.2.1 Historical Trend (2016-2022)
 - 10.2.2 Forecast Trend (2023-2031)
 - 10.3 Germany
 - 10.3.1 Historical Trend (2016-2022)
 - 10.3.2 Forecast Trend (2023-2031)
 - 10.4 France
 - 10.4.1 Historical Trend (2016-2022)
 - 10.4.2 Forecast Trend (2023-2031)
 - 10.5 Italy
 - 10.5.1 Historical Trend (2016-2022)
 - 10.5.2 Forecast Trend (2023-2031)
 - 10.6 Others
- 11 Asia Pacific Hypophosphatasia Treatment Market
 - 11.1 Market Share by Country
 - 11.2 China
 - 11.2.1 Historical Trend (2016-2022)
 - 11.2.2 Forecast Trend (2023-2031)
 - 11.3 Japan
 - 11.3.1 Historical Trend (2016-2022)
 - 11.3.2 Forecast Trend (2023-2031)
 - 11.4 India
 - 11.4.1 Historical Trend (2016-2022)
 - 11.4.2 Forecast Trend (2023-2031)
 - 11.5 ASEAN
 - 11.5.1 Historical Trend (2016-2022)
 - 11.5.2 Forecast Trend (2023-2031)
 - 11.6 Australia
 - 11.6.1 Historical Trend (2016-2022)
 - 11.6.2 Forecast Trend (2023-2031)
 - 11.7 Others
- 12 Latin America Hypophosphatasia Treatment Market
 - 12.1 Market Share by Country
 - 12.2 Brazil
 - 12.2.1 Historical Trend (2016-2022)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.2 Forecast Trend (2023-2031)
- 12.3 Argentina
 - 12.3.1 Historical Trend (2016-2022)
 - 12.3.2 Forecast Trend (2023-2031)
- 12.4 Mexico
 - 12.4.1 Historical Trend (2016-2022)
 - 12.4.2 Forecast Trend (2023-2031)
- 12.5 Others
- 13 Middle East and Africa Hypophosphatasia Treatment Market
 - 13.1 Market Share by Country
 - 13.2 Saudi Arabia
 - 13.2.1 Historical Trend (2016-2022)
 - 13.2.2 Forecast Trend (2023-2031)
 - 13.3 United Arab Emirates
 - 13.3.1 Historical Trend (2016-2022)
 - 13.3.2 Forecast Trend (2023-2031)
 - 13.4 Nigeria
 - 13.4.1 Historical Trend (2016-2022)
 - 13.4.2 Forecast Trend (2023-2031)
 - 13.5 South Africa
 - 13.5.1 Historical Trend (2016-2022)
 - 13.5.2 Forecast Trend (2023-2031)
 - 13.6 Others
- 14 Global Hypophosphatasia Treatment Market Dynamics
 - 14.1 Market Drivers and Constraints
 - 14.2 SWOT Analysis
 - 14.3 Porter's Five Forces Model
 - 14.4 Key Demand Indicators
 - 14.5 Key Price Indicators
 - 14.6 Industry Events, Initiatives, and Trends
 - 14.7 Value Chain Analysis
- 15 Supplier Landscape
 - 15.1 Kirin Holdings Company
 - 15.1.1 Company Overview
 - 15.1.2 Product Portfolio
 - 15.1.3 Demographic Reach and Achievements
 - 15.1.4 Mergers and Acquisitions
 - 15.1.5 Certifications
 - 15.2 Vericel Corporation
 - 15.2.1 Company Overview
 - 15.2.2 Product Portfolio
 - 15.2.3 Demographic Reach and Achievements
 - 15.2.4 Mergers and Acquisitions
 - 15.2.5 Certifications
 - 15.3 Mereo BioPharma Group plc
 - 15.3.1 Company Overview
 - 15.3.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 Novartis AG
 - 15.4.1 Company Overview
 - 15.4.2 Product Portfolio
 - 15.4.3 Demographic Reach and Achievements
 - 15.4.4 Mergers and Acquisitions
 - 15.4.5 Certifications
- 15.5 Bayer AG
 - 15.5.1 Company Overview
 - 15.5.2 Product Portfolio
 - 15.5.3 Demographic Reach and Achievements
 - 15.5.4 Mergers and Acquisitions
 - 15.5.5 Certifications
- 15.6 AM-Pharma B.V.
 - 15.6.1 Company Overview
 - 15.6.2 Product Portfolio
 - 15.6.3 Demographic Reach and Achievements
 - 15.6.4 Mergers and Acquisitions
 - 15.6.5 Certifications
- 15.7 Alexion
 - 15.7.1 Company Overview
 - 15.7.2 Product Portfolio
 - 15.7.3 Demographic Reach and Achievements
 - 15.7.4 Mergers and Acquisitions
 - 15.7.5 Certifications
- 15.8 Pfizer, Inc.
 - 15.8.1 Company Overview
 - 15.8.2 Product Portfolio
 - 15.8.3 Demographic Reach and Achievements
 - 15.8.4 Mergers and Acquisitions
 - 15.8.5 Certifications
- 16 Hypophosphatasia Treatment Market- Distribution Model (Additional Insight)
 - 16.1 Overview
 - 16.2 Potential Distributors
 - 16.3 Key Parameters for Distribution Partner Assessment
- 17 Payment Methods (Additional Insight)
 - 17.1 Government Funded
 - 17.2 Private Insurance
 - 17.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Hypophosphatasia Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-11 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-15"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com